Evaluation of Candidemia in Solid-Organ Transplant Recipients

Exp Clin Transplant. 2024 Jan;22(Suppl 1):160-166. doi: 10.6002/ect.MESOT2023.O39.

Abstract

Objectives: Solid-organ transplant recipients have high rates of invasive fungal infections. Candida species are the most commonly isolated fungi. Our aim was to identify risk factors, clinical presentations, and outcomes of candidemia in solid-organ transplant recipients.

Materials and methods: We evaluated adult (≥18 years old) transplant recipients seen from May 2011 to December 2022 at Baskent University Ankara Hospital. From medical records, we retrospectively reviewed age, sex, transplant type, candidemia agent, risk factors, concomitant infections, and mortality of patients with Candida detected in blood culture. We used SPSS statistics software (version 25) to analyze data.

Results: There were 1080 organ transplants performed during the study period (717 kidney, 279 liver, 84 heart). There were 855 who were ≥18 years (655 kidney, 127 liver, 73 heart), of whom candidemia was detected in 26 (16 male; 11 kidney, 11 liver, 4 heart) with a median age of 47.5 years. The most common agents were Candida albicans and Candida glabrata. The most common chronic diseases were hypertension, cirrhosis, and cardiomyopathy. Eighteen patients had a concomitant focus of infection. Ten patients had pneumonia accompanying candidemia. The 30-day mortality rate was as high as 53.8%. The mean duration of candidemia after transplant was 23 months. Catheter-related candidemia was observed in 65% of patients. The 30-day mortality was found to be significantly higher in patients followed in the intensive care unit (P = .014), receiving total parenteral nutrition (P = .001), using broad-spectrum antibiotics (P = .001), and having pneumonia (P = .042) accompanying candidemia.

Conclusions: For adult solid-organ transplant recipients with candidemia, careful monitoring is essential for successful management of total parenteral nutrition, central catheter, use of broadspectrum antibiotics, and invasive interventions.

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents
  • Antifungal Agents / therapeutic use
  • Candida
  • Candidemia* / diagnosis
  • Candidemia* / drug therapy
  • Candidemia* / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation* / adverse effects
  • Pneumonia* / etiology
  • Retrospective Studies
  • Risk Factors
  • Transplant Recipients

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents